Welcome to the Biognosys News archive
Biognosys adds beta support for diaPASEF within Spectronaut, the industry leading data-independent acquisition (DIA) proteomics software.
Webinar with Dr. Christine Carapito on September 24th, 2019 – 4.00 PM (CEST).
Two abstracts on Biognosys’ new workflows will be presented at the Society for Neuroscience (SfN) Annual Meeting in Chicago, Illinois from October 19-23, 2019.
Biognosys closes Series G round with new and existing investors to accelerate implementation of discovery proteomics in clinical trials.
Biognosys attends ASMS 2019 with an array of posters, orals and exhibition booth (#517)
Biognosys to present new data on applications of HRMTM mass spectrometry to support research for therapeutic development and clinical investigations
Biognosys Introduces Two Major Software Updates and Pushes the Standards of Next Generation Proteomics
Unlocking Big Tissue Biobanks: Analyzing the Proteome Using SWATH® Acquisition and Spectronaut Analysis
Roche presents data from a mock clinical trial study suggesting that next generation discovery proteomics is ready for use in clinical trials.
We proudly present our most recent publication on the “Comparison of protein quantification in a complex background by DIA and TMT workflows with fixed instrument time.”; the result...
Mass-Spectrometry as an Unbiased Tool to Discover, Identify and Quantify Protein Biomarkers
It begins now. The new era in proteomics.
The new era in discovery proteomics.
Unbiased and proteome-wide profiling of protein conformational changes
Biognosys’ Discovery Proteomics Service was used to quantify hundreds of proteins in patients with glaucoma
Exploring the potential of using targeted proteomics for the high throughput quantification of protein expression after mRNA administration
If you haven’t yet registered we still have a couple of places left. We will send the recording of the webinar afterwards to all registrants.
We look forward to meeting you at the 21st International Mass Spectrometry Conference in Toronto
We are happy to announce that Biognosys was involved in the development of the human SRMAtlas, a collection of proteomic assays for any human protein.
Targeted Proteomics has been named "Method of the year 2012" by Nature Methods
Biognosys founder Johan Malmstroem publishes landmark paper in the field of targeted proteomics and infectious disease in Nature Communications.
We have closed an intermediate financing round with incumbent and new investors allowing us to further expand our business in Europe and the US.
Our recent paper is published in the latest issue of Proteomics 8/12
The Swiss Commission for Technology and Innovation (CTI) has granted CHF 1.5m for a research collaboration between Biognosys and the group of Prof. Aebersold, ETH Zurich, to bring the novel HRM-MS technology to the market.
Biognosys collaborates with M2 to develop commercial MRM software
Biognosys attracted venture capital from experienced investors including Syngenta Ventures.
Biognosys ranked #12 of TOP100 Swiss Start-Ups and #3 among Life Science companies.
Biognosys is invited to present its iRT concept for mass spectrometry specialists.
On September 9th, 2011, Biognosys turns 3 years old...
Siena, Italy: Biognosys AG is entering into a collaboration with Novartis Vaccines and Diagnostics.
The world's most validated library of mass spec assays
Biognosys is lecturing and exhibiting at the American Society for Mass Spectrometry Conference 2011 in Denver, Colorado (swing by Booth 28 if you’re attending).
Let us help you do great proteomics!
Please click here to contact us.